PRME
Price
$2.92
Change
+$0.13 (+4.66%)
Updated
Dec 20, 04:59 PM (EDT)
74 days until earnings call
RXRX
Price
$6.04
Change
-$0.05 (-0.82%)
Updated
Dec 20, 04:59 PM (EDT)
72 days until earnings call
Ad is loading...

PRME vs RXRX

Header iconPRME vs RXRX Comparison
Open Charts PRME vs RXRXBanner chart's image
Prime Medicine
Price$2.92
Change+$0.13 (+4.66%)
Volume$59.31K
CapitalizationN/A
Recursion Pharmaceuticals
Price$6.04
Change-$0.05 (-0.82%)
Volume$233.5K
CapitalizationN/A
PRME vs RXRX Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. RXRX commentary
Dec 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and RXRX is a Hold.

COMPARISON
Comparison
Dec 22, 2024
Stock price -- (PRME: $2.90 vs. RXRX: $6.03)
Brand notoriety: PRME and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 204% vs. RXRX: 186%
Market capitalization -- PRME: $382.99M vs. RXRX: $2.36B
PRME [@Biotechnology] is valued at $382.99M. RXRX’s [@Biotechnology] market capitalization is $2.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, RXRX is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 6 bearish.
  • RXRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than PRME.

Price Growth

PRME (@Biotechnology) experienced а +0.69% price change this week, while RXRX (@Biotechnology) price change was -13.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

PRME is expected to report earnings on Mar 06, 2025.

RXRX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.36B) has a higher market cap than PRME($383M). RXRX YTD gains are higher at: -38.844 vs. PRME (-67.269). PRME has higher annual earnings (EBITDA): -207.13M vs. RXRX (-350.86M). RXRX has more cash in the bank: 428M vs. PRME (176M). PRME has less debt than RXRX: PRME (41.2M) vs RXRX (90.6M). RXRX has higher revenues than PRME: RXRX (64.6M) vs PRME (800K).
PRMERXRXPRME / RXRX
Capitalization383M2.36B16%
EBITDA-207.13M-350.86M59%
Gain YTD-67.269-38.844173%
P/E RatioN/AN/A-
Revenue800K64.6M1%
Total Cash176M428M41%
Total Debt41.2M90.6M45%
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
73
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
88
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PRMERXRX
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
68%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 5 days ago
81%
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRGKX37.810.41
+1.10%
iShares Russell 1000 Large-Cap Idx K
VYSZX5.800.06
+1.05%
Voya Small Company C
TRIIX4.780.02
+0.42%
Catalyst/SMH Total Return Income I
HSWTX17.85-0.01
-0.06%
Hartford Schroders International Stk R5
HNMDX13.53-0.57
-4.04%
Heartland Mid Cap Value Institutional

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+3.94%
CRSP - PRME
63%
Loosely correlated
+0.83%
BEAM - PRME
61%
Loosely correlated
+8.04%
NTLA - PRME
59%
Loosely correlated
+0.83%
RXRX - PRME
56%
Loosely correlated
-0.99%
ABCL - PRME
55%
Loosely correlated
+5.17%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-0.99%
CRSP - RXRX
62%
Loosely correlated
+0.83%
BEAM - RXRX
61%
Loosely correlated
+8.04%
PRME - RXRX
56%
Loosely correlated
+3.94%
NTLA - RXRX
54%
Loosely correlated
+0.83%
EXAI - RXRX
52%
Loosely correlated
N/A
More